Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the operating margin high or low?
The operating margin of 28.94% is 101% above its 5-year average of -4434.91%, near the high end of its 5-year range (-541000.00%–71.97%).
100.97% above its 12-month average of -2996.12%.
Reported quarterly operating margin; no daily interpolation. Q2 FY2026 (2026-06-30): 0.00%.
OPERATING MARGIN
28.94%
OPERATING MARGIN AVG TTM
-2996.12%
OPERATING MARGIN AVG 3Y
-11152.39%
OPERATING MARGIN AVG 5Y
-4434.91%
OPERATING MARGIN AVG 10Y
N/A
OPERATING MARGIN AVG 15Y
N/A
OPERATING MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+100.97%
CURRENT VS 3Y AVG
+100.26%
CURRENT VS 5Y AVG
+100.65%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.00%
median of 600 covered companies
CURRENT VS SECTOR MEDIAN
N/A
vs the sector median at left
Keros Therapeutics, Inc.
Market Cap
$224.74M
Operating Margin
28.94%
TTM Avg
-2996.12%
3Y Avg
-11152.39%
5Y Avg
-4434.91%
Market Cap
$225.24M
Operating Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$230.05M
Operating Margin
-48.72%
TTM Avg
-61.63%
3Y Avg
-124.59%
5Y Avg
-150.09%
Market Cap
$230.29M
Operating Margin
-31.37%
TTM Avg
-39.87%
3Y Avg
-74.09%
5Y Avg
-70.30%
Market Cap
$218.58M
Operating Margin
66.70%
TTM Avg
45.54%
3Y Avg
40.90%
5Y Avg
43.81%
Market Cap
$233.80M
Operating Margin
-1026.28%
TTM Avg
-515.73%
3Y Avg
-257.87%
5Y Avg
-257.87%
Market Cap
$215.30M
Operating Margin
6.67%
TTM Avg
9.41%
3Y Avg
-3.44%
5Y Avg
-14.56%
Market Cap
$215.11M
Operating Margin
40.94%
TTM Avg
-5.20%
3Y Avg
-130.22%
5Y Avg
-446.71%
Market Cap
$236.09M
Operating Margin
9.95%
TTM Avg
-10.78%
3Y Avg
-18.24%
5Y Avg
-54.36%
| NAME | MARKET CAP | OPERATING MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Keros Therapeutics, Inc. (KROS) | $224.74M | 28.94% | -2996.12% | -11152.39% | -4434.91% |
| Nautilus Biotechnolgy, Inc. (NAUT)vs › | $225.24M | 0.00% | 0.00% | 0.00% | 0.00% |
| MacroGenics, Inc. (MGNX)vs › | $230.05M | -48.72% | -61.63% | -124.59% | -150.09% |
| Biodesix, Inc. (BDSX)vs › | $230.29M | -31.37% | -39.87% | -74.09% | -70.30% |
| Anbio Biotechnology Class A Ordinary Shares (NNNN)vs › | $218.58M | 66.70% | 45.54% | 40.90% | 43.81% |
| BioAge Labs Inc. (BIOA)vs › | $233.80M | -1026.28% | -515.73% | -257.87% | -257.87% |
| Niagen Bioscience Inc (NAGE)vs › | $215.30M | 6.67% | 9.41% | -3.44% | -14.56% |
| Compugen Ltd. (CGEN)vs › | $215.11M | 40.94% | -5.20% | -130.22% | -446.71% |
| Akebia Therapeutics, Inc. (AKBA)vs › | $236.09M | 9.95% | -10.78% | -18.24% | -54.36% |
| Lyell Immunopharma, Inc. (LYEL)vs › | $212.94M | -566038.89% | -577080.92% | -336097.22% | -224856.35% |
Gross Margin
94.7%
Operating Margin
28.9%
Operating Margin = Operating Income / Revenue
Operating margin is the percentage of revenue remaining after operating expenses, reflecting operating efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | OPERATING MARGIN |
|---|---|
| 2026-06-30 | 0.00% |
| 2026-03-31 | -7050.95% |
| 2025-12-31 | -7602.60% |
| 2025-09-30 | -107.87% |
| 2025-06-30 | -219.16% |
| 2025-03-31 | 71.97% |
| 2024-12-31 | -1750.62% |
| 2024-09-30 | -15117.78% |
| 2024-06-30 | -136321.62% |
| 2024-03-31 | -58413.25% |
| 2023-12-31 | -32486.01% |
| 2023-09-30 | -541000.00% |
| 2023-06-30 | 0.00% |
| 2023-03-31 | 0.00% |
| 2022-12-31 | 0.00% |
| 2022-09-30 | 0.00% |
| 2022-06-30 | 0.00% |
| 2022-03-31 | 0.00% |
| 2021-12-31 | -24.33% |
| 2021-09-30 | 0.00% |
| 2021-06-30 | -15541.00% |
| 2021-03-31 | 0.00% |
| 2020-12-31 | 0.00% |
| 2020-09-30 | 0.00% |
| 2020-06-30 | 0.00% |
| 2020-03-31 | 0.00% |
| 2019-12-31 | -109.12% |
| 2019-09-30 | -93.04% |
| 2019-06-30 | -106.04% |
| 2019-03-31 | -114.32% |
